Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Aditya Bardia Komal L Jhaveri Seock-Ah Im Sonia Pernas Michelino De Laurentiis Shu-Sen WangNoelia Martínez JañezGiuliano BorgesDavid W Cescon Masaya Hattori Yen-Shen Lu Erika Paige HamiltonQingyuan ZhangJunji Tsurutani Kevin M Kalinsky Pedro Emanuel Rubini LiedkeLu XuRick M FairhurstSabrina Khan Neelima Denduluri Hope S Rugo Binghe Xu Barbara Pistillinull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

Patients receiving Dato-DXd had statistically significant and clinically meaningful improvement in PFS and a favorable and manageable safety profile, compared with ICC. Results support Dato-DXd as a novel treatment option for patients with inoperable/metastatic HR+/HER2‒ breast cancer who have received one to two previous lines of chemotherapy in this setting.

Keyphrases